These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 12168866)

  • 21. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
    Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
    Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
    Hefler LA; Zeillinger R; Grimm C; Sood AK; Cheng WF; Gadducci A; Tempfer CB; Reinthaller A
    Gynecol Oncol; 2006 Nov; 103(2):512-7. PubMed ID: 16750560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
    Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
    Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
    Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-operative prediction of serum CA125 level in women with ovarian masses.
    Benjapibal M; Neungton C
    J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
    Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
    APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
    Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
    Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
    Kang S; Seo SS; Park SY
    J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.